PDF(Pubmed)
Abstract：
The aim of this study was to explore the safety and efficacy of multiple peptide-pulsed autologous dendritic cells (DCs) combined with cytotoxic T lymphocytes (CTLs) in patients with cancer.
Five patients diagnosed with cancer between November 2020 and June 2021 were enrolled and received DC-CTLs therapy. Peripheral blood was collected and antigenic peptides were analyzed. The phenotype and function of DC-CTLs and the immune status of patients were detected using flow cytometry or IFN-γ ELISPOT analysis.
DCs acquired a mature phenotype and expressed high levels of CD80, CD86, CD83, and HLA-DR after co-culture with peptides, and the DC-CTLs also exhibited high levels of IFN-γ. Peripheral blood mononuclear cells from post-treatment patients showed a stronger immune response to peptides than those prior to treatment. Importantly, four of five patients maintained a favorable immune status, of which one patient\'s disease-free survival lasted up to 28.2 months. No severe treatment-related adverse events were observed.
Our results show that multiple peptide-pulsed DCs combined with CTLs therapy has manageable safety and promising efficacy for cancer patients, which might provide a precise immunotherapeutic strategy for cancer.
Five patients diagnosed with cancer between November 2020 and June 2021 were enrolled and received DC-CTLs therapy. Peripheral blood was collected and antigenic peptides were analyzed. The phenotype and function of DC-CTLs and the immune status of patients were detected using flow cytometry or IFN-γ ELISPOT analysis.
DCs acquired a mature phenotype and expressed high levels of CD80, CD86, CD83, and HLA-DR after co-culture with peptides, and the DC-CTLs also exhibited high levels of IFN-γ. Peripheral blood mononuclear cells from post-treatment patients showed a stronger immune response to peptides than those prior to treatment. Importantly, four of five patients maintained a favorable immune status, of which one patient\'s disease-free survival lasted up to 28.2 months. No severe treatment-related adverse events were observed.
Our results show that multiple peptide-pulsed DCs combined with CTLs therapy has manageable safety and promising efficacy for cancer patients, which might provide a precise immunotherapeutic strategy for cancer.
摘要：
■这项研究的目的是探讨多肽脉冲的自体树突状细胞（DC）与细胞毒性T淋巴细胞（CTL）联合治疗癌症患者的安全性和有效性。
■在2020年11月至2021年6月期间，有5名被诊断患有癌症的患者被招募并接受DC-CTL治疗。收集外周血并分析抗原肽。使用流式细胞术或IFN-γELISPOT分析检测DC-CTL的表型和功能以及患者的免疫状态。
■DC与肽共培养后获得了成熟的表型，并表达高水平的CD80，CD86，CD83和HLA-DR，和DC-CTL也表现出高水平的IFN-γ。来自治疗后患者的外周血单核细胞显示出比治疗前更强的对肽的免疫应答。重要的是,五名患者中有四名保持了良好的免疫状态，其中一名患者的无病生存期长达28.2个月。未观察到严重的治疗相关不良事件。
■我们的结果表明，多肽脉冲DC联合CTL治疗对癌症患者具有可控的安全性和有希望的疗效，这可能为癌症提供精确的免疫治疗策略。
■在2020年11月至2021年6月期间，有5名被诊断患有癌症的患者被招募并接受DC-CTL治疗。收集外周血并分析抗原肽。使用流式细胞术或IFN-γELISPOT分析检测DC-CTL的表型和功能以及患者的免疫状态。
■DC与肽共培养后获得了成熟的表型，并表达高水平的CD80，CD86，CD83和HLA-DR，和DC-CTL也表现出高水平的IFN-γ。来自治疗后患者的外周血单核细胞显示出比治疗前更强的对肽的免疫应答。重要的是,五名患者中有四名保持了良好的免疫状态，其中一名患者的无病生存期长达28.2个月。未观察到严重的治疗相关不良事件。
■我们的结果表明，多肽脉冲DC联合CTL治疗对癌症患者具有可控的安全性和有希望的疗效，这可能为癌症提供精确的免疫治疗策略。
